Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 5/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CTPS1 | P17812 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3435480 | 0.93 | MAPT (0.48) | MAPTCYP3A4BLMPMP22NPC1 | |
| SCHEMBL28086239 | 0.90 | ALDH1A1 (0.52) | MAPTCYP3A4BLMPMP22NPC1 | |
| SCHEMBL31729425 | 0.90 | ALDH1A1 (0.52) | MAPTCYP3A4BLMPMP22NPC1 | |
| SCHEMBL4934814 | 0.86 | MAPT (0.55) | MAPTCYP3A4BLMPMP22NPC1 | |
| SCHEMBL5789102 | 0.81 | POLB (0.44) | MAPTCYP3A4BLMPMP22NPC1 | |
| SCHEMBL5792626 | 0.81 | TSHR (0.48) | MAPTCYP3A4NPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL27763626 | 0.81 | ALDH1A1 (0.52) | MAPTCYP3A4NPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL16166721 | 0.78 | KDM4E (0.61) | MAPTNPC1ALDH1A1SMN1; SMN2LMNA | |
| Tretazicar SCHEMBL5805671 | 0.76 | MAPT (0.69) | MAPTCYP3A4BLMPMP22NPC1 | |
| SCHEMBL8773146 | 0.76 | TSHR (0.51) | MAPTCYP3A4NPC1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9193687-B2 | Phenyl N-mustard linked to DNA-affinic molecules or water-soluble aryl rings, method and their use as cancer therapeutic agents | ACADEMIA SINICA (TW) | 2015-11-24 | — | — | US | disclosed |
| US-20130178494-A1 | PHENYL N-MUSTARD LINKED TO DNA-AFFINIC MOLECULES OR WATER-SOLUBLE ARYL RINGS, METHOD AND THEIR USE AS CANCER THERAPEUTIC AGENTS | ACADEMIA SINICA (TW) | 2013-07-11 | — | — | US | disclosed |
| EP-1109550-B1 | NOVEL NITROPHENYLAZIRIDINE COMPOUNDS AND THEIR USE AS PRODRUGS | AUCKLAND UNISERVICES LTD (NZ) | 2004-11-24 | — | — | EP | disclosed |
| US-6517836-B1 | Aziridin-1-yl nitrobenzamides as prodrugs in conjunction with nitroreductase enzymes | AUCKLAND UNISERVICES LIMITED (NZ) | 2003-02-11 | — | — | US | disclosed |
| EP-1109550-A2 | NOVEL NITROPHENYLAZIRIDINE COMPOUNDS AND THEIR USE AS PRODRUGS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000013683-A3 | NOVEL NITROPHENYLAZIRIDINE COMPOUNDS AND THEIR USE AS PRODRUGS | CANCER RES CAMPAIGN TECH (GB) | 2000-07-13 | — | — | WO | disclosed |
| WO-2000013683-A2 | NOVEL NITROPHENYLAZIRIDINE COMPOUNDS AND THEIR USE AS PRODRUGS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2000-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178494-A1 | PHENYL N-MUSTARD LINKED TO DNA-AFFINIC MOLECULES OR WATER-SOLUBLE ARYL RINGS, METHOD AND THEIR USE AS CANCER THERAPEUTIC AGENTS | PCNA, WEE1, UNG | MAPT 3624/4885CYP3A4 3812/4885BLM 746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.